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A large subgroup of around 25% of schizophrenia patients suffers from
obsessive-compulsive symptoms (OCS) and about 12% fulfill the diagnostic criteria
of an obsessive-compulsive disorder (OCD). The additional occurrence of OCS is
associated with high subjective burden of disease, additional neurocognitive impairment,
poorer social and vocational functioning, greater service utilization and high levels of
anxiety and depression. Comorbid patients can be assigned to heterogeneous subgroups.
One hypothesis assumes that second generation antipsychotics (SGAs), most importantly
clozapine, might aggravate or even induce second-onset OCS. Several arguments support
this assumption, most importantly the observed chronological order of first psychotic
manifestation, start of treatment with clozapine and onset of OCS. In addition, correlations
between OCS-severity and dose and serum levels and duration of clozapine treatment hint
toward a dose-dependent side effect. It has been hypothesized that genetic risk-factors
dispose patients with schizophrenia to develop OCS. One study in a South Korean sample
reported associations with polymorphisms in the gene SLC1A1 (solute carrier family 1A1)
and SGA-induced OCS. However, this finding could not be replicated in European patients.
Preliminary results also suggest an involvement of polymorphisms in the BDNF gene
(brain-derived neurotrophic factor) and an interaction between markers of SLC1A1 and the
gene DLGAP3 (disc large associated protein 3) as well as GRIN2B (N-methyl-D-aspartate
receptor subunit 2B). Further research of well-defined samples, in particular studies
investigating possible interactions of genetic risk-constellations and pharmacodynamic
properties, are needed to clarify the assumed development of SGA-induced OCS. Results
might improve pathogenic concepts and facilitate the definition of at risk populations,
early detection and monitoring of OCS as well as multimodal therapeutic interventions.
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GENE AND ENVIRONMENT INTERACTIONS IN PSYCHIATRIC
DISORDERS
Several frequent and disabling mental disorders manifest as
a consequence of both genetic and environmental factors.
Schizophrenia for instance is commonly perceived on the back-
ground of a gene-and-environment interaction (GxEI), where
individual genetic properties dispose to a specific liability and
sensitivity for specific stressors. These could include migration,
other stressful life events, or effects of psychotropic substances
(van Os and Kapur, 2009; van Os et al., 2008, 2010). Similar
concepts were suggested regarding depression (Keers and Uher,
2012), anxiety disorders (Gregory et al., 2008; Nugent et al.,
2011) and obsessive-compulsive disorder (OCD) (Nicolini et al.,
Abbreviations: AMS, amisulpride; APZ, aripiprazole; ARMS, at risk mental state;
BDNF, brain derived neurotrophic factor; CBT, cognitive behavioral therapy; CLZ,
clozapine; DLGAP3, disks large associated protein 3; GxEI: Gene and environment
interaction; OCS, obsessive-compulsive symptoms; OCD, obsessive-compulsive
disorder; OLZ, olanzapine; SGA, second generation antipsychotics; SLC1A1, solute
carrier family gene 1A1; SNP, single nucleotide polymorphism; SSRI, selective
serotonin reuptake inhibitor.
2009; Pauls, 2010). Expanding the view to common comor-
bidities it is even more complex and demanding to inves-
tigate whether these might also be described on the basis
of GxEI.
In this review we summarize evidence investigating possi-
ble pharmacological and genetic risk constellations underlying
the co-occurrence of comorbid obsessive-compulsive symptoms
(OCS) in schizophrenia.
EPIDEMIOLOGY OF OCS IN SCHIZOPHRENIA
Patients with schizophrenia have a high lifetime risk of about
25% for comorbid OCS and a recent meta-analysis reports that
12.1% also fulfill the criteria for an OCD (Figure 1C; Poyurovsky
et al., 2004, 2012; Buckley et al., 2009; Lysaker and Whitney,
2009; Mukhopadhaya et al., 2009; Achim et al., 2011; Hadi et al.,
2011). In contrast, prevalence rates of 1–2% for OCD in the gen-
eral population are considerably lower (Murphy et al., 2010).
Accordingly, primary OCD-patients carry a relatively low risk
(1.7%) to develop comorbid psychotic symptoms (de Haan et al.,
2009).
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FIGURE 1 | Prevalence estimations of OCS and OCD within different
samples of patients. (A) Mean prevalence rates in ARMS studies. (B)
Mean prevalence rates in first-episode psychotic patients. (C) Mean
prevalence rates in patients suffering from chronic schizophrenia.
Schizophrenia patients, who suffer from comorbid OCS often
also display pronounced and sometimes treatment resistant posi-
tive and negative symptoms (Cunill et al., 2009; Sa et al., 2009).
In addition, they present with specific neurocognitive deficits
(Schirmbeck et al., 2012b), more often utilize health care services
(Berman et al., 1995a), and show heightened levels of anxiety
and depression (Lysaker and Whitney, 2009) when compared to
schizophrenia patients without OCS. These pronounced impair-
ments result in an additional burden of disease, in poorer social
and vocational function (Fenton and McGlashan, 1986; Lysaker
et al., 2004; Öngür and Goff, 2005; de Haan et al., 2013) and in a
less favorable overall prognosis (Schirmbeck and Zink, 2013).
CLINICAL PRESENTATION AND EXPLANATORY CONCEPTS
Several heterogeneous subgroups of comorbid patients have been
suggested depending on the diverse clinical course and phe-
notypic presentation. In order to unravel the specific interplay
of genetic, psychosocial and pharmacological factors current
research tries to focus on homogeneous subgroups. Subdivisions
into such subgroups can for example be achieved according to the
time point of first manifestation of comorbidOCS and the clinical
course.
ONSET OF OCS
First onset of OCS has been described at different stages during
the course of psychotic illness:
(1) Before psychosis as independent, co-existing symptoms or
diagnosed OCD.
(2) Prior to psychotic manifestation as part of the at risk mental
state (ARMS).
(3) Simultaneously with the first manifestation of psychosis.
(4) After the first psychotic episode during the course of chronic
schizophrenia.
(5) As de novo OCS after initiation of antipsychotic treatment.
A remarkably large subgroup of patients already suffers fromOCS
during ARMS. Overall, sample-size weighted mean prevalence
rates show that 12.1% (CI: 9.4–14.8%) of ARMS patients report
OCS (Shioiri et al., 2007; Niendam et al., 2009; Bechdolf et al.,
2011; Sterk et al., 2011; Hur et al., 2012), while 5.2% (CI: 4.1–
6.3%) fulfill the criteria for OCD (Shioiri et al., 2007; Niendam
et al., 2009; Rubino et al., 2009; Bechdolf et al., 2011; Fontenelle
et al., 2011; DeVylder et al., 2012; Fusar-Poli et al., 2012; Sterk
et al., 2011) (Figure 1A). Slightly higher averaged rates for OCS
(17.1%, CI: 14.0–20.2) and OCD (7.3%, CI: 5.3–9.3%) can be
found in first episode patients (Figure 1B; Poyurovsky et al.,
1999a; de Haan et al., 2004; Sterk et al., 2011; de Haan et al.,
2012; Zink et al., under review). Large variability of epidemio-
logical data between studies can be explained by differences in
the definition of ARMS criteria and differences in the psychome-
tric assessment of OCS or OCD. Regarding the impact of OCS
during the ARMS on other clinical variables, findings have been
heterogeneous. Whereas higher impairment of psychosocial func-
tioning (de Haan et al., 2012; DeVylder et al., 2012; Fusar-Poli
et al., 2012; Hur et al., 2012) and more severe depressive symp-
toms (Niendam et al., 2009; DeVylder et al., 2012; Fontenelle
et al., 2012; de Haan et al., 2013) have consistently been reported,
findings regarding transition rates into psychosis (Niendam et al.,
2009; Fontenelle et al., 2011, 2012; Fusar-Poli et al., 2012) and
cognition (Van Dael et al., 2011){4854}(Hur et al., 2012) are
contradicting.
Apart from OCS during the ARMS a growing body of evi-
dence investigated the co-occurrence of OCS during mani-
fest schizophrenia. A significant subgroup within these patients
reports OCS development after treatment-start with second gen-
eration antipsychotic agents (SGA). The order of the three
events “onset of psychosis,” “start with SGA treatment” and
subsequent “de novo development of OCS” hints toward the
involvement of pharmacodynamic mechanisms (see Figure 2E
and detailed description in section OCS induced by second-
generation antipsychotics).
CLINICAL COURSE
In addition to varying time-points of first manifestation of
OCS, the course of symptom severity over time also differs
(Figure 2). OCS may appear as fluctuating symptoms, they
may resolve, persist or even worsen over time. Within those
patients who already reported manifest OCD prior to the psy-
chotic illness, e.g., as adolescents, OCS will most likely persist
or worsen independent of the course of schizophrenia (Hwang
et al., 2009). Within those individuals who develop OCS some-
time during the course of schizophrenia, only scarce longitu-
dinal studies examined quantitative changes over time. One
large investigation from the Netherlands followed participants
over a period of 5 years and described a predominantly fluc-
tuating course of OCS severity in over 70% of the comorbid
sample: Some patients experienced the remission of OCS, oth-
ers a fluctuating, more or less cyclic course, some reported
first onset of OCS, whereas a forth group showed persisting
symptom severity (Mahasuar et al., 2011). Another longitudi-
nal study in a German sample investigated two pharmacolog-
ical diverse groups and found persisting OCS severity over 12
months in the group treated with clozapine (CLZ) and olan-
zapine (OLZ) (Schirmbeck et al., 2012b, 2013). The diverse
clinical course adds to the heterogeneous clinical presentation
and suggests an involvement of different environmental fac-
tors and/or symptom interactions in the longitudinal devel-
opment of comorbid OCS in schizophrenia (see section
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FIGURE 2 | OCS might manifest at different time points during the
course of schizophrenia illness. In addition, the clinical course is highly
variable. Blue symbols indicate the onset and severity of OCS, red ones are
related to psychotic symptoms. (A) Pre-existing and persistent OCS. (B)
Intermittent OCS during ARMS or later in the clinical course. (C) OCS-onset
during ARMS and persistent course, strongly associated to the psychotic
symptoms (schizo-obsessive concept). (D) Fluctuating course of OCS. (E)
Second-onset OCS during antipsychotic treatment.
Underlying neurobiological mechanisms and environmental
factors).
Furthermore, specific symptom dimensions of schizophrenia
might overlap with the obsessive-compulsive phenotype (Fink
and Taylor, 2001), making a careful differentiation and classi-
fication of presented symptoms necessary. Especially in cases
of catatonic schizophrenia (Fink, 2013), a reliable assessment
with established psychometric scales such as the catatonia rating
scale (CRS) (Bräunig et al., 2000) and the Yale-Brown-Obsessive-
Compulsive Scale (YBOCS) (Woody et al., 1995; de Haan et al.,
2006) is often difficult. Historically, a more precise character-
ization was achieved by an undisguised view on the natural
long-term course of schizophrenia, for instance published by
Karl Leonhard (Beckmann et al., 2000). These descriptions allow
clear discrimination between OCS and catatonic symptoms most
importantly in patients with so-called “manneristic catatonia.”
Clinical research and an improved pathogenic understanding
of OCS in patients with schizophrenia is thus dependent on a
careful exploration of symptoms. Several aspects help to discrimi-
nate delusions or hallucinations from typical OCS to ensure valid
and reliable diagnosis (see Table 1).
PATHOGENIC CONCEPTS
In attempts to explain the co-occurrence of OCS in schizophre-
nia, heterogeneous, partly overlapping but also contradicting
pathogenic concepts have been suggested.
The two rather common psychiatric syndromes could of
course develop independently, representing a random associa-
tion. Based on the above mentioned high prevalence rates and
diverse clinical presentation this cannot be the only explanation
for OCS in nearly every fourth patient with schizophrenia.
Early concepts assumed that patients with schizophre-
nia develop OCS as an attempt to reduce psychotic symp-
toms and thus, the presence of OCS was proposed to have
protective effects regarding psychotic disintegration, based
on single-case analyses or small case series (Stengel, 1945;
Dowling et al., 1995). Similarly, Guillem et al. described
negative correlations between specific OCS and the sever-
ity of psychotic disorganization in thinking and behavior,
proposing compensating mechanisms (Guillem et al., 2009).
However, in a broader perspective, subsequent research revealed
higher severity of psychotic symptoms and more functional
impairment if OCS were present (Cunill et al., 2009) (see
above).
Approaching the co-occurrence from the OCD spec-
trum, the concept of “schizotypic OCD” has been described
(Poyurovsky and Koran, 2005; Poyurovsky et al., 2008). This
concept assumes that primary OCD-patients present beliefs,
which can be classified on a spectrum between obsessions
and delusions emphasizing the similarities as being irra-
tional thoughts, the first with insight and the latter lacking
insight. In line with this concept, the category of “obses-
sions without insight” was integrated into the fourth edition
of the Diagnostic and Statistical Manual (DSM IV). OCD-
patients without insight might therefore represent a subgroup
with genetic, phenotypic and therapeutic vicinity to the
schizophrenia-like spectrum (Tumkaya et al., 2009; Catapano
et al., 2010).
Approaching the co-occurrence from the schizophrenia spec-
trum, a so-called “schizo-obsessive” subtype of psychosis has
been proposed, based on cross-sectional evaluations (Poyurovsky,
2013). This subtype has been suggested to comprise OCS in
addition to positive, negative and cognitive schizophrenia symp-
toms (Poyurovsky et al., 2012). Similar concepts have been
proposed by Hwang et al. (2000), Bottas et al. (2005), and
Reznik et al. (2001, 2005). Attempts to validate the “schizo-
obsessive” subtype on a neurobiological level have been incon-
sistent. Some studies proposed specific neurological features
(Sevincok et al., 2006; Poyurovsky et al., 2007b), cognitive deficits
(Lysaker et al., 2002, 2009) and even structural abnormalities
(Gross-Isseroff et al., 2003).
The mentioned high prevalence rates of OCS in the ARMS,
led to the perception that specific OCS could be a part of
the basic symptom cluster in the early course of schizophrenia
(Sullwold and Huber, 1986; Ebel et al., 1989).
The summarized pathogenic concepts mirror the high degree
of heterogeneity within the comorbid sample. They are currently
discussed and the number of publications on this topic nearly
doubles every year.
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Table 1 | Identification of obsessive-compulsive symptoms in schizophrenia.
Insight-criterion Patients suffering from OCD typically fulfill three symptom characteristics: they attribute the obsessions, impulsive
symptoms and compulsions to their own thinking, declare with insight their unreasonableness and show some
degree of resistance against them. In particular the first two properties allow a differentiation from hallucinations
and delusions. Ruminations or stereotypic ego-dystonic cognitions with direct relation to the contents to psychotic
thinking should not be diagnosed as obsessions.
OCS not solely related to the
psychotic content
Cleaning or checking behavior should be diagnosed as compulsions only if it is accompanied by typical obsessions
and not, if the patient currently suffers from delusions of contamination, intoxication or infection.
Re-evaluation of OCS after
remission of psychotic symptoms
If first manifestation of OCS occurs simultaneously with the first psychotic exacerbation, the final decision on a
valid comorbid condition should be postponed until the remission of psychotic symptoms.
Differentiation from catatonic
symptoms
Repetitive behavior or stereotypic actions should carefully be discriminated from catatonic symptoms most
importantly in patients with so-called “manieristic catatonia.”
Obsessions presented as
pseudohallucinations
A subgroups of OCS patients, who experience their obsessions as extremely aversive and burdening may try to
distance themselves by using expressions such as “voices” or “foreign thought content”, but in most cases these
phenomena can be characterized as pseudohallucinations.
SGA-induced OCS Patients without a previous history of OCS might develop these phenomena during antipsychotic treatment. This
constellation hints toward the unfavorable effect of second-onset OCS induced by SGAs.
Clinical aspects that have to be considered when differentiating between psychotic symptoms (delusions, hallucinations) and OCS.
UNDERLYING NEUROBIOLOGICAL MECHANISMS AND
ENVIRONMENTAL FACTORS
Neurobiology
While the described explanatory concepts mainly follow a clin-
ical or psychopathological rationale, several investigations tried
to improve the pathogenic understanding from a neurobiological
perspective. So far, most emphasis has been given to a mul-
timodal neurocognitive characterization. Preliminary investiga-
tions of neurological soft signs (Sevincok et al., 2006; Poyurovsky
et al., 2007b) and neuroimaging techniques (Gross-Isseroff et al.,
2003) need replication.
For primary OCD recent reviews of published literature
reported specific cognitive deficits especially in the areas of cog-
nitive shifting abilities, inhibitory control and the application of
effective planning strategies (Kuelz et al., 2004). Based on these
findings, the question arose whether OCS in schizophrenia might
also be linked to additional cognitive impairment in these OCD-
related domains (Lysaker andWhitney, 2009). Subsequently, sev-
eral authors tried to differentiate schizophrenia samples with vs.
without comorbid OCS on the basis of their neuropsychological
performance. Findings have been contradicting. Whereas some
investigations did not find any significant differences (Hermesh
et al., 2003; Whitney et al., 2004; Öngür and Goff, 2005; Tumkaya
et al., 2009; Tiryaki and Ozkorumak, 2010; Achim et al., 2011;
Meijer et al., 2013), others even suggested that OCS may be asso-
ciated with better cognitive abilities (Lee et al., 2009; Borkowska
et al., 2013), especially in the prodromal states of schizophrenia
(Van Dael et al., 2011; Fontenelle et al., 2012; Hur et al., 2012;
Zink et al., under review). Most results, however, showed more
pronounced deficits in the described domains of executive func-
tioning (Hwang et al., 2000; Lysaker et al., 2002, 2009), cognitive
flexibility (Kumbhani et al., 2010; Patel et al., 2010), and also
delayed visual memory (Berman et al., 1998; Schirmbeck et al.,
2011).
In a recent longitudinal assessment, Lysaker et al. prospec-
tively analyzed executive functioning and reported that deficits
were linked to greater concurrent and prospective self-report
of OCS among schizophrenia patients (Lysaker et al., 2009). A
comprehensive prospective investigation by Schirmbeck et al.
explicitly included OCD-related cognitive domains in their anal-
ysis (Kuelz et al., 2004; Rajender et al., 2011). Over a period of 12
months schizophrenia patients with comorbid OCS showed sig-
nificant pronounced deficits with increasing effect sizes regarding
cognitive flexibility, visuo-spatial perception, and visual mem-
ory. Performance in these domains correlated with OCS severity
(Schirmbeck et al., 2012b).
Based on these findings and with respect to possible causal
pathways, it has been proposed that pronounced cognitive deficits
reflect an underlying neurobiological risk factor for schizophrenia
patients to develop OCS and mirror at least partially overlap-
ping neurobiological mechanisms with OCD. In order to further
substantiate this hypothesis neurobiological links that explain the
pronounced deficits in the comorbid sample should be iden-
tified. Therefore, research should focus on candidate regions,
which have been described in primary OCD, such as increased
activation-levels in the orbitofrontal cortex (Whiteside et al.,
2004; Friedlander and Desrocher, 2006)using fMRI approaches.
Regarding neurotransmission, current pathogenic theories of
OCD assume a central serotonergic dysfunction in a network
comprising cortical, striatal and thalamic centers (Pogarell et al.,
2003). Corresponding evidence is provided by the therapeu-
tic effects of selective serotonin reuptake inhibitors (SSRIs) and
cognitive behavioral therapy (CBT) in OCD (Linden, 2006;
Saxena et al., 2009). In addition, neuroimaging studies with
structural and functional methods confirmed alterations in the
suggested network (Friedlander and Desrocher, 2006; Menzies
et al., 2008; Kwon et al., 2009a). Based on these findings it has
been assumed that the strong serotonergic antagonism of CLZ
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(Coward, 1992; Meltzer and Huang, 2008; Meltzer, 2012) and
OLZ (Duggan et al., 2000) constitute a pathogenic mechanism in
the development of second-onset OCS in schizophrenia (for more
detail see section Epidemiological evidence and Pharmacological
evidence). However, apart from serotonergic dysfunctions, alter-
ations in dopaminergic activity (Van der Wee et al., 2004) and in
glutamatergic neurotransmission, have also been related to OCD:
Support for the involvement of glutamate in the development of
OCD comes from animal models (Joel, 2006; Albelda et al., 2010;
Yang and Lu, 2011), human MR spectroscopy (Whiteside et al.,
2006; Starck et al., 2008), treatment approaches addressing the
glutamatergic system (Coric et al., 2005; Poyurovsky et al., 2005,
2010; Lafleur et al., 2006; Pittenger et al., 2006) and the following
results from genetic investigations.
Genetic disposition
Previous family and twin studies suggest a strong heritability
of OCD (Nicolini et al., 2009; Pauls, 2010). In contrast, results
from genetic association studies with a primary focus on candi-
date genes of serotonergic and dopaminergic neurotransmission
were rather ambiguous. So far, only one linkage finding has con-
sistently been replicated, which refers to single nucleotide poly-
morphisms (SNP) in the gene SLC1A1 (solute carrier family) on
chromosome 9p24, encoding the neuronal glutamate transporter
EAAC1 (excitatory amino acid carrier 1) (Veenstra-VanderWeele
et al., 2001; Arnold et al., 2006; Dickel et al., 2006; Stewart et al.,
2007; Shugart et al., 2009; Wendland et al., 2009).
Possible neurogenetic disposition to develop OCS during the
course of psychotic illness has just recently become a focus of
interest. Research within this field is still scarce and needs further
exploration. Progress has been achieved within a specific sub-
group, suggesting a genetic disposition to develop OCS during
SGA treatment (see section Genetic disposition).
Environmental factors
As briefly mentioned above, the majority of comorbid patients
reports large fluctuation of OCS severity as either remitting,
de novo development or intermittent OCS. However, the effect
of environmental factors on onset or symptom severity as well
as on interactions with other psychopathological processes has
scarcely been investigated. Thus, the small number of longitu-
dinal studies leaves important aspects unresolved. These include
the following questions: (1) Do dynamic OCS and psychotic
symptoms follow a parallel course? (2) Does a causal interac-
tion of symptom variability exist? (3) Does experienced stress,
life-events or antipsychotic medication influence the severity and
course of OCS? Detailed follow-up analyses of the potential influ-
ence of environmental factors are therefore needed. Patients,
who recently reported changes in their OCS should be investi-
gated by means of an ‘Experience Sampling Method’ (ESM). This
approach captures the reactivity to environmental factors and
the course of symptoms in detail on a day to day basis, in real
life situations, which allows to resolve symptom interactions and
contextual triggers of variability. Results could provide the basis
for individualized interventions, including adjusted modules of
cognitive behavioral therapy (CBT).
Inconsistent results regarding associated neurobiological
and environmental factors are most probably a consequence
of the reported heterogeneity within the comorbid sample.
Furthermore, methodological concerns such as the restriction to
mainly cross-sectional evaluations and a lack of power due to
small sample sizes add to inconclusive findings.
Thus, progress in pathogenic understanding seems most
likely if future research focuses on the detailed characteriza-
tion of homogeneous subsamples. One recent very promising
approach has been achieved within the subgroup of patients
who develop secondary OCS during SGA treatment. The fol-
lowing section summarizes evidence supporting the hypothe-
sis of SGA-induced OCS and introduces possible genetic risk
factors.
OCS INDUCED BY SECOND-GENERATION ANTIPSYCHOTICS
The subgroup of patients who report first onset or aggravation of
OCS after psychotic manifestation and treatment initiation with
SGAs has been brieflymentioned above. The simple assessment of
the order of three important events (first psychotic manifestation,
start of antipsychotic treatment and subsequent onset of OCS)
helps to define this subgroup (Lykouras et al., 2003; Schirmbeck
and Zink, 2012; Schirmbeck et al., 2013). The observation that
schizophrenia patients develop OCS after psychotic manifesta-
tion and treatment initiation is mainly linked to SGAs and has
rarely been reported under first generation antipsychotics. Several
authors related this observation to the fact that SGAs carry the
important pharmacodynamic feature of balanced antidopamin-
ergic and antiserotonergic properties, which markedly exceed
the low affinity of first generation antipsychotics to serotonergic
receptors (Meltzer, 1995; Meltzer et al., 2003). In addition, differ-
ential effects on GABAergic and glutamatergic neurotransmission
have to be considered (Lopez-Gil et al., 2010).
The hypothesis of SGA-inducedOCS as a side-effect (Lykouras
et al., 2003; Kwon et al., 2009b) first arose after the pioneer
observations of Baker et al. (1992) and de Haan et al. (1999).
Since then several studies show a clear association and possi-
ble causal interaction between SGA-treatment, most importantly
CLZ (Schirmbeck and Zink, 2012), and the de novo occurrence of
OCS (de Haan et al., 2004; Reznik et al., 2004; Kwon et al., 2009b;
Schirmbeck et al., 2011).
Without a doubt, CLZ must be considered an indispensable
part of the antipsychotic armament (Joober and Boksa, 2010;
Kang and Simpson, 2010; Kane, 2011; Meltzer, 2012), especially
in cases with otherwise treatment resistant psychoses (Kane et al.,
1988). Several investigations (Asenjo Lobos et al., 2010) includ-
ing the CATIE-study (McEvoy et al., 2006) have demonstrated
its superior antipsychotic efficacy (Gupta and Daniel, 1995; Still
et al., 1996; Kelly et al., 2003). Therefore, CLZ is considered the
antipsychotic of first choice in treatment resistant schizophrenia.
In addition, the substance demonstrates important anti-suicidal
effects resulting in lowmortality rates of CLZ-treated schizophre-
nia patients (Tiihonen et al., 2009). However, within a variety
of other important side effects (Asenjo Lobos et al., 2010), the
de novo occurrence or exacerbation of OCS under antipsychotic
treatment has most often been observed with CLZ (Lykouras
et al., 2003; Reznik et al., 2004; Schirmbeck and Zink, 2012).
Due to a lack of controlled clinical trials, proposed causal inter-
relations cannot be confirmed, according to the general criteria
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suggested by Bradford Hill (2011). Nevertheless, several epi-
demiological (Epidemiological evidence) and pharmacological
(Pharmacological evidence) arguments support this assumption
(for summary see Table 2).
EPIDEMIOLOGICAL EVIDENCE
Increase of OCS prevalence after market approval of SGAs
Only few investigations reported comorbidity rates in sam-
ples treated with first generation antipsychotics (Fenton and
McGlashan, 1986; Berman et al., 1995a,b; Nolfe et al., 2010). After
market approval of SGAs, most importantly CLZ, in the 1970s in
Europe and the late 1980s in the USA (Hippius, 1989; Kang and
Simpson, 2010), prevalence estimations markedly rose. Although
a potential publication bias and increased general awareness of
this topic needs to be considered, these data provide a first indirect
hint toward a possible interrelation.
Higher OCS prevalence during the chronic course of schizophrenia
As mentioned, prevalence estimations on OCS and OCD in
ARMS and first episode samples clearly vary (see Figure 1 and
section Onset of OCS). However, when compared to established
rates of 12% (OCD) and 25% (OCS) in chronic schizophrenia,
they appear to be significantly smaller. The higher rates in the later
stages of the disease might partly be attributed to antipsychotic
treatment.
Onset of de novo OCS during antipsychotic treatment or marked
aggravation
Several case reports and cases series, as well as systematic evalua-
tions describe the de novo emergence of OCS during the treatment
with atypical antipsychotics, most importantly CLZ (Schirmbeck
and Zink, 2012). Poyurovski et al. estimated that up to 70%
of schizophrenia patients treated with mainly antiserotonergic
SGAs such as CLZ, OLZ or risperidone develop secondary OCS
(Poyurovsky et al., 2004), while Lykouras et al. reviewed pub-
lished data and even reported de novo OCS in 77% of CLZ
treated patients (Lykouras et al., 2003). Independent studies
reported high proportions of SGA-induced OCS within samples
of comorbid patients: 25 of 28 (89%) (Schirmbeck et al., 2011),
29 of 39 (74%) (Lin et al., 2006) and 23 of 26 (88%) (Lim et al.,
2007). Furthermore, retrospective assessments of the individual
disease histories show that most patients experience the onset
of OCS after first manifestation of psychosis and the start with
SGA-treatment (Schirmbeck et al., 2012a) (Figure 3).
PHARMACOLOGICAL EVIDENCE
A variety of studies contribute to the assumption that antisero-
tonergic SGAs have pro-obsessive effects.
Higher prevalence of OCS in samples treated with CLZ
The risk for comorbid OCS markedly differs if patients are strat-
ified according to their mode of antipsychotic treatment. As
FIGURE 3 | In this sample of 44 comorbid patients the survival-curve
shows the events “start of SGA treatment” and “first onset of OCS”
on an individual basis related to the first manifestation of psychosis.
The longitudinal course of OCS shows a high degree of variability and is not
depicted here. The graphs shows that in all but 7 cases OCS developed
subsequently to psychosis and the vast majority of patients reported OCS
onset after treatment-start with SGAs (Schirmbeck et al., 2012a).
Table 2 | Arguments supporting SGA-induction of OCS.
Epidemiology The prevalence rates of OCS in schizophrenia increased after market approval of clozapine (Schirmbeck and Zink, 2012).
The comorbidity rates in later disease stages are higher than at first manifestation of schizophrenia (see Figure 1).
Schizophrenia patients with comorbid OCS are most frequently found to be treated with clozapine. Vice versa high OCS prevalence
in patients treated with clozapine (Poyurovsky et al., 2004; Lim et al., 2007; Poyurovsky et al., 2007a; Schirmbeck et al., 2011).
Pharmacology The type of antipsychotic treatment is associated with the risk for OCS: Marked difference between samples treated with first
generation antipsychotics or mainly dopaminergic SGAs (such as aripiprazole or amisulpride) compared to clozapine (Ertugrul et al.,
2005; Sa et al., 2009; Schirmbeck et al., 2011).
OCS manifest as a unfavorable drug effect de novo during treatment with potent antiserotonergic SGAs such as clozapine (see
Figure 3) (Schirmbeck and Zink, 2012).
The severity of OCS is positively correlated with duration, dosage and serum levels of clozapine treatment (Lin et al., 2006;
Schirmbeck et al., 2011).
The OCS severity is found stable over time in patients under stable clozapine treatment (Schirmbeck et al., 2013).
The severity of OCS improves after reduction of clozapine dosage to minimally sufficient levels (due to augmentation or
combination) (Rocha and Hara, 2006; Zink et al., 2006; Englisch et al., 2009).
Summary of epidemiological and pharmacological arguments supporting the assumption that OCS can be induced or at least markedly aggravated by SGA-treatment
as an unfavorable side effect (Schirmbeck et al., 2012b).
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reported, high prevalence rates in CLZ-treated patients (Ertugrul
et al., 2005), contrast with low rates during treatment with first
generation antipsychotics, for instance, haloperidol (Sa et al.,
2009) or other SGAs. Differences in pharmacodynamic prop-
erties, in particular regarding inherent serotonergic blockade,
monoaminergic reuptake inhibition or even partial serotoner-
gic agonism might explain these diverging findings (Shapiro
et al., 2003; Meltzer and Huang, 2008; Meltzer and Sumiyoshi,
2008; Remington, 2008; Lopez-Gil et al., 2010). Interestingly,
Aripiprazole (APZ), a partial dopaminergic and serotonergic ago-
nist, was associated with an inherent anti-obsessive effect in
schizophrenia patients with OCS (Connor et al., 2005; Zink et al.,
2006; Chang et al., 2008; Englisch and Zink, 2008; Englisch et al.,
2009), quite similar to amisulpride (AMS), a dopamine D3/D2
receptor antagonist (Kim et al., 2008; Pani et al., 2008). A compar-
ison of schizophrenia patients under antipsychotic monotherapy
with either mainly antiserotonergic SGAs (CLZ or OLZ; group I)
or mainly dopaminergic SGAs (AMS or APZ; group II) revealed
that more than 70% of group-I-patients suffered from OCS while
less than 10% of patients in group-II reported OCS (Schirmbeck
et al., 2011). Vice versa, a stratification of schizophrenia patients
according to presence or absence of comorbid OCS revealed that
77% of comorbid patients were treated with clozapine while
only 36% of schizophrenia patients without OCS received this
substance (Lim et al., 2007). These results clearly suggest an asso-
ciation between CLZ treatment and comorbid OCS. However, a
possible confounding effect due to the selection of specific SGAs
for specific subgroups of patients has to be considered.
Noteworthy, in some cases an alleviation of OCS severity
after the addition of CLZ (Peters and de, 2009), an increase
in CLZ dosage (Lykouras et al., 2003) or start with OLZ treat-
ment (van Nimwegen et al., 2008; Poyurovsky, 2013) has been
observed. Regarding these contradicting findings, some impor-
tant aspects should be discussed. One explanation relates to the
abovementioned diagnostic difficulties to differentiation between
OCS and delusional or catatonic symptoms (Table 1). Patients
with schizophrenia, who show obsessive ruminations or stereo-
typic thoughts during acute psychosis or repetitive ritualized
behavior clearly related to the patient’s primary psychotic con-
dition might indeed benefit from treatment with CLZ. Thus,
careful diagnostic evaluations are necessary. Furthermore, anti-
obsessive effects of antipsychotics have also been reported in
primary OCD, including OLZ, especially in cases with treatment-
resistance to serotonergic antidepressants (Bloch et al., 2006;
Bandelow et al., 2008; Dold et al., 2011; Muscatello et al., 2011).
Nevertheless, even in treatment-resistant OCD current treat-
ment guidelines do not recommend CLZ as an augmentation
strategy.
Associations between the duration of treatment and OCS severity
Correlations between pharmacological variables and OCS pro-
vide further support for proposed causal interactions. Lin et al.
(2006) compared CLZ-treated patients with and without comor-
bid OCS and found significantly longer CLZ treatment periods
for the comorbid group, but no difference in duration of illness.
Schirmbeck et al. reported a positive correlation between OCS
severity and duration of CLZ-treatment (Schirmbeck et al., 2011).
Accordingly, de Haan et al. reported this association for OLZ (de
Haan et al., 2002).
ASSOCIATION BETWEEN DOSAGE AND BLOOD SERUM LEVELS AND
OCS SEVERITY
Several authors demonstrated positive correlations between dose
or serum levels of CLZ and severity of OCS (Lin et al., 2006;
Reznik et al., 2004; Mukhopadhaya et al., 2009; Schirmbeck
et al., 2011). Similarly, a reduction of daily CLZ-dosage, for
instance through the combinations with another SGA, such as
APZ, resulted in an alleviation of OCS severity (Rocha and Hara,
2006; Zink et al., 2006; Englisch et al., 2009). This observed effect
might represent both a reduction of the suggested dose-related
side effect of CLZ and/or a consequence of inherent anti-obsessive
effects of APZ due to its partial dopaminergic and serotoner-
gic agonism. The latter assumption was supported by a placebo
controlled randomized trial, which showed reduced OCS severity
after combination with APZ, but unchanged CLZ dose during the
course of the study (Chang et al., 2008).
Differential effects of SGAs on the course of OCS
A recent longitudinal study revealed differential effects of antipsy-
chotic agents on comorbid OCS. Within a 12 months obser-
vational period, changes in YBOCS scores significantly differed
between two pharmacologically diverse groups (completer anal-
ysis: p = 0.006; full sample analysis: p = 0.007). Whereas the
CLZ/OLZ group showed persistently high OCS severity over time,
the AMS/APZ group reported further decrease of the initially low
YBOCS-scores (Schirmbeck et al., 2013).
In conclusion, reported data show strong associations between
comorbid OCS in schizophrenia and mainly antiserotonergic
SGAs, most importantly CLZ. The published epidemiologi-
cal and pharmacological evidence hint toward causal interac-
tions, suggesting CLZ’s strong inherent antiserotonergic proper-
ties (Steingard et al., 1993; Joober and Boksa, 2010; Kang and
Simpson, 2010), most importantly the antagonism at 5-HT1C,
5-HT2A and 5HT2C receptors (Coward, 1992; Meltzer, 1994;
Meltzer and Huang, 2008) as an relevant underlying mechanism.
Low affinities to dopamine receptors result in a very small ratio of
dopaminergic/serotonergic receptor blockade, which largely dif-
fers from SGAs such as AMS or APZ (Scatton et al., 1997; Shapiro
et al., 2003; Correll, 2008). In addition, reciprocal interactions
of dopaminergic and serotonergic neurotransmission with glu-
tamatergic and GABAergic functions might play an important
role (Lopez-Gil et al., 2010). Thus, pharmacotherapy constitutes
a relevant environmental factor, which might exert pro-obsessive
effects in schizophrenia patients. Within a broader perspective,
additional questions arise concerning predisposing factors. These
might comprise patient-inherent characteristics (neurocognitive
profile, the subtype of psychosis, the stage of the illness, any kind
of affective comorbidity or a family history for anxiety disorders)
and the individual genetic disposition.
GENETIC DISPOSITION
Associations with the gene SLC1A1 have consistently been repli-
cated in primary OCD patients. Based on these findings a
South Korean research group investigated the genetic risk to
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develop second-onset OCS during treatment with SGAs (Kwon
et al., 2009b). Kwon et al evaluated associations between spe-
cific SNPs of the candidate gene SLC1A1 and SGA-induced OCS
and showed strong associations with the A/C/G dominant haplo-
type rs2228622 / rs3780413 / rs37801412. The odds ratio of 3.96
indicated an almost 4 times higher likelihood for patients, who
carried this A/C/G haplotype to suffer from SGA-induced OCS.
Neither the gene SLC1A1 nor its chromosomal region has been
associated with vulnerability to schizophrenia spectrum disorders
(Deng et al., 2007). The same group further described a genetic
interaction of the SLC1A1 polymorphism with variants in the
geneDLGAP3 (disks large associated protein 3) and a link to SGA-
induced OCS (Ryu et al., 2011). In addition, Cai et al reported
on an interaction of SNPs in SLC1A1 and the type 2B subunit
of the N-methyl-D-aspartate receptor gene (GRIN2B), as well as
interactions with the YBOCS score in Chinese patients (Cai et al.,
2013).
A replication approach of the results obtained by Kwon et al.
(2009b) was conducted in 103 schizophrenia patients of European
descent treated with SGAs. However, the described finding could
not be reproduced, neither in single marker, nor in haplotype
analyses. Because no genetic associations between SLC1A1 poly-
morphisms and OCS were found within the power limits of
this study, much larger samples seem necessary to untangle the
interplay of pharmacological and genetic risk factors for OCS
in schizophrenia (Schirmbeck et al., 2012a). The brain derived
neurotrophic factor (BDNF) was recently proposed as a third can-
didate gene, because the Val66Met polymorphism was found to
be associated with OCS in schizophrenia (Hashim et al., 2012).
So far, independent replication approaches regarding BDNF,
DLGAP3 and GRIN2B have not been conducted.
RESEARCH PERSPECTIVES
GxEI ON A SECOND LEVEL OF COMPLEXITY
GxEIs are core elements within current theories of schizophrenia
(van Os and Kapur, 2009; van Os et al., 2008, 2010), depres-
sion (Keers and Uher, 2012), anxiety disorders (Gregory et al.,
2008; Nugent et al., 2011) and OCD (Nicolini et al., 2009; Pauls,
2010). High rates of bi-directional comorbidities lead to the obvi-
ous question, if these co-occurrences could also be explained by
common GxEIs. One example of this experimental psychopathol-
ogy has been illustrated by the described investigation of the risk
to develop secondary OCS during treatment with SGAs. Here,
the environmental factor is represented in the pharmacological
treatment of schizophrenia with pro-obsessive SGAs.
As stated in chapter 4, SGAs increase the risk for secondary
OCS via a pharmacodynamic mechanism. Independently, a set
of SNPs within the gene SLC1A1 seem to predispose to OCD.
However, the initially reported high odds ratio by Kwon et al.
(2009b) could not be replicated in a similar study performed with
European patients (Schirmbeck et al., 2012a). Thus, the general
genetic background of a patient (Asian or European) might be of
importance when a specific SGA (balance between dopaminer-
gic and serotonerigic blockade) is introduced as the treatment of
choice. Furthermore, gene-x-gene interactions (SNPs in SLC1A1,
BDNF, DLGAP3, and GRIN2B) have been suggested as further
influencing factors (Ryu et al., 2011; Hashim et al., 2012) and
should be considered in forthcoming studies. It is an important
progress in recent neurobiological research to investigate how
the interaction of these factors might influence the propensity of
schizophrenia patients to suffer from comorbid OCS when being
treated with SGAs.
Future progress might depend on two aspects: First, well
defined homogeneous clinical cohorts should be defined to
reduce the number of possible confounding causal factors to a
minimum. Considering the order of symptom onset, the clin-
ical course and the applied treatment for sample characteriza-
tion might be helpful. Second, much larger cohorts have to be
recruited in multicenter studies to investigate possible genetic
risk constellations. If power analyses would be based on the
much smaller genetic-risk estimations for the gene SLC1A1 in the
European sample (Schirmbeck et al., 2012a), group size calcula-
tions result in about five thousand participants, which would be
necessary for replication.
Besides pharmacological treatment as a relevant factor, fur-
ther non-pharmacological environmental factors could play an
important role in the development of OCS in schizophrenia.
Such factors might include, psychosocial stress induced by critical
life events, interpersonal factors, changes of the vocational situ-
ation or the present state of general physical health. In addition,
the reciprocal interaction and possible causal directions between
OCS and psychotic positive, negative and cognitive symptoms
of schizophrenia must be unraveled and considered. One impor-
tant tool to unravel the interdependence of these variables are the
above described experience sampling approaches. These allow to
investigate the individual symptom variability in real life situa-
tions on a day to day basis.
Collected data will help to identify the time course of
symptom-changes and its relation to important environmental
factors. These studies are currently planned and will hopefully
result in an improved understanding of etiological factors influ-
encing the course of OCS in schizophrenia. Within this context it
will also be desirable to collect DNA samples in order to analyse
possible predisposing effects of the above mentioned polymor-
phisms to experience the development or aggravation of OCS
after being exposed to stressful life events. Thus, combining expe-
rience sampling and genetic characterizations might markedly
improve our insight into GxEI.
THERAPY
At present, pharmacological treatment interventions, most
importantly combination as well as augmentation strategies, have
been suggested to improve OCS in the highly impaired comorbid
group (Schirmbeck et al., 2013). To address possible pro-obsessive
effects of predominantly anti-serotonergic SGAs, the add-on of
mainly dopaminergic SGAs such as AMS and APZ has been pro-
posed (Connor et al., 2005; Zink et al., 2006; Englisch and Zink,
2008; Kim et al., 2008; Yang et al., 2008; Englisch et al., 2009;
Muscatello et al., 2011). In addition, the augmentation with sero-
tonergic antidepressants has been evaluated, for example with the
tricyclic antidepressant clomipramine (Berman et al., 1995b) or
with SSRIs, most often fluvoxamine (Poyurovsky et al., 1999b;
Reznik and Sirota, 2000; Hwang et al., 2009). Results of these trials
have been inconsistent with some studies failing to observe the
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Table 3 | Therapeutic approaches.
Early recognition
and monitoring
Definition of at-risk-constellations.
Monitoring of subclinical levels of OCS or beginning cognitive impairment using sensitive sets of neurocognitive tests
(Schirmbeck et al., 2011, 2012b).
Polypharmacy Augmentation with antidepressants: Clomipramine, fluvoxamine and other SSRIs. [Level of evidence: RCTs, CS, CR] (Berman
et al., 1995b; Poyurovsky et al., 1999b; Reznik and Sirota, 2000).
Caveat: Additive (anticholinergic) side effects and pharmacokinetic interactions
Augmentation with mood stabilizers (lamotrigine, valproic acid) aiming at a reduction of SGA-dosage to minimally sufficient levels
[Level of evidence: CS, CR] (Zink et al., 2007; Poyurovsky et al., 2010; Rodriguez et al., 2010; Canas et al., 2012).
Combination of pro-obsessive SGAs with neutral or anti-obsessive SGAs (amisulpride, aripiprazole) in order to reduce the
clozapine-dosage to minimally sufficient levels [Level of evidence: RCT, CS, CR].
(Connor et al., 2005; Zink et al., 2006; Englisch and Zink, 2008; Kim et al., 2008; Yang et al., 2008; Englisch et al., 2009;
Muscatello et al., 2011)
Psychotherapy Cognitive behavioral therapy involving exposure and response prevention [Level of evidence: CS, CR] (Schirmbeck and Zink, 2012;
Tundo et al., 2012).
Summary of therapeutic approaches for schizophrenia patients with comorbid OCS or OCD. The current level of empirical evidence is indicated in square brackets.
Abbreviations: CR, case report; CS, case series; RCT, randomized controlled trial.
intended effects of OCS reduction. Furthermore, additive anti-
cholinergic side effects and pharmacokinetic interactions have
to be considered. Finally, first promising results were published
reporting on the augmentation with mood stabilizers such as val-
proic acid (Zink et al., 2007; Canas et al., 2012) or lamotrigine
(Poyurovsky et al., 2010; Rodriguez et al., 2010).
So far, very limited data exists on the efficacy and safety of cog-
nitive behavioral therapy (CBT) for this group of patients. The
small number of case reports and case series can hardly be rec-
onciled with the fact, that CBT including exposure and response
prevention is considered treatment of first choice for primary
OCD with remarkably high effect sizes (Gava et al., 2007; Koran
et al., 2007; Rosa-Alcazar et al., 2008; Kuelz and Voderholzer,
2011). With one exception, currently available CBT manuals for
OCD do not provide guidelines for the treatment of OCS in
schizophrenia (Emmelkamp and van Oppen, 2000; Lakatos and
Reinecker, 2007; Oelkers et al., 2007; Foerstner et al., 2011).
However, a summary of the published reports on 30 comor-
bid patients (Schirmbeck et al., 2013), who were treated with
CBT including exposure elements or just exposure and response
prevention alone showed favorable outcome measures with sig-
nificant reduction of OCD severity in 24 patients. In the included
case series by Tundo et al. (2012) 52% of investigated individuals
were classified as “much or very much” improved, 33% as respon-
ders and 19% as remitters. The available evidence of CBT for OCS
in schizophrenia is certainly limited by the small case numbers
and further controlled clinical trials are needed. However, despite
adverse clinical outcomes in 10%, and a total dropout rate of
20%, preliminary results suggest meaningful and marked reduc-
tion of OCS severity in 80% of participants (Schirmbeck et al.,
2013). Table 3 summarizes possible pharmacological and non-
pharmacological approaches and current evidence of empirical
support.
CONCLUSIONS
The summarized data substantiate the conclusions that OCS is
a very frequent and relevant comorbid burden in schizophre-
nia. The clinical presentation of the co-occurrence is very diverse,
suggesting different subgroups with heterogeneous pathogenic
mechanisms. First insight into GxEI has been achieved for the
subgroup of patients who experienced second-onset OCS during
treatment with SGAs. In the future, a broader set of environ-
mental variables, including non-pharmacological factors, and
further genetic risk-constellations should be analysed, starting
in the ARMS. In perspective, this will not only improve the
risk prediction regarding comorbid OCS, but also early recog-
nition and monitoring of emerging symptoms. Research within
this field will further provide the individual framework of predis-
posing and disease-provoking factors with immediate impact for
pharmacological and CBT approaches.
REFERENCES
Achim, A. M., Maziade, M., Raymond,
E., Olivier, D., Merette, C., and
Roy, M. A. (2011). How prevalent
are anxiety disorders in schizophre-
nia? A meta-analysis and critical
review on a significant association.
Schizophr. Bull. 37, 811–821. doi:
10.1093/schbul/sbp148
Albelda, N., Bar-On, N., and Joel, D.
(2010). The role of NMDA receptors
in the signal attenuation rat model
of obsessive-compulsive disorder.
Psychopharmacology 210, 13–24.
doi: 10.1007/s00213-010-1808-9
Arnold, P. D., Sicard, T., Burroughs,
E., Richter, M. A., and Kennedy,
J. L. (2006). Glutamate trans-
porter gene SLC1A1 associated
with obsessive-compulsive dis-
order. Arch. Gen. Psychiatry 63,
769–776. doi: 10.1001/archpsyc.
63.7.769
Asenjo Lobos, C., Komossa, K.,
Rummel-Kluge, C., Hunger,
H., Schmid, F., Schwarz, S.,
et al. (2010). Clozapine versus
other atypical antipsychotics for
schizophrenia. Cochrane Database
Syst. Rev. 11:CD006633. doi:
10.1002/14651858.CD006633.pub2
Baker, R. W., Chengappa, K. N.,
Baird, J. W., Steingard, S., Christ,
M. A., and Schooler, N. R.
(1992). Emergence of obsessive
compulsive symptoms during
treatment with clozapine. J. Clin.
Psychiatry 53, 439–442. doi:
10.1080/15622970802465807
Bandelow, B., Zohar, J., Hollander,
E., Kasper, S., ller, H. J., WFSBP
Task Force on Treatment Guidelines
for Anxiety, O.-C. a. P.-T. S. D.,
et al. (2008). World Federation of
Societies of Biological Psychiatry
(WFSBP) guidelines for the
pharmacological treatment of
anxiety, obsessive-compulsive
and post-traumatic stress dis-
orders - first revision. World J.
Biol. Psychiatry 9, 248–312. doi:
10.1080/15622970802465807
www.frontiersin.org August 2013 | Volume 4 | Article 99 | 9
Schirmbeck and Zink Obsessions and compulsions in schizophrenia
Bechdolf, A., Mueller, H., Stoetzer,
H., Wagner, M., Maier, W.,
Lautenschlager, M., et al. (2011).
Rationale and baseline char-
acteristics of PREVENT: a
second-generation intervention
trial in subjects at-risk (Prodromal)
of developing first-episode psy-
chosis evaluating cognitive behavior
therapy, aripiprazole, and placebo
for the prevention of psychosis.
Schizophr. Bull. 37, S111–S121. doi:
10.1093/schbul/sbr083
Beckmann, H., Bartsch, A. J.,
Neumärker, K.-J., Pfuhlmann,
B., Verdaguer, M. F., and Franzek,
E. (2000). Schizophrenias in the
Wernicke-Kleist-Leonhard school.
Am. J. Psychiatry 157, 1024–1025.
doi: 10.1176/appi.ajp.157.6.1024-a
Berman, I., Kalinowski, A., Berman,
S. M., Lengua, J., and Green, A. I.
(1995a). Obsessive and compulsive
symptoms in chronic schizophre-
nia. Compr. Psychiatry 36, 6–10. doi:
10.1016/0010-440X(95)90092-A
Berman, I., Sapers, B. L., Chang, H.
H., Losonczy, M. F., Schmildler, J.,
and Green, A. I. (1995b). Treatment
of obsessive-compulsive symp-
toms in schizophrenic patients
with clomipramine. J. Clin.
Psychopharmacol. 15, 206–210.
doi: 10.1097/00004714-199506000-
00009
Berman, I., Merson, A., Viegner, B.,
Losonczy, M. F., Pappas, D., and
Green, A. I. (1998). Obsessions
and compulsions as a distinct clus-
ter of symptoms in schizophre-
nia: a neuropsychological study.
J. Nerv. Ment. Dis. 186, 150–156.
doi: 10.1097/00005053-199803000-
00003
Bloch, M. H., Landeros-Weisenberger,
A., Kelmendi, B., Coric, V., Bracken,
M. B., and Leckman, J. F. (2006).
A systematic review: antipsychotic
augmentation with treatment
refractory obsessive-compulsive dis-
order. Mol. Psychiatry 11, 622–632.
doi: 10.1038/sj.mp.4001823
Borkowska, A., Pilaczynska, E., and
Rybakowski, J. K. (2013). The
frontal lobe neuropsychological
tests in patients with schizophrenia
and/or obsessive-compulsive dis-
order. J. Neuropsychiatry Clin.
Neurosci. 15, 359–362. doi:
10.1176/appi.neuropsych.15.3.359
Bottas, A., Cooke, R. G., and Richter,
M. A. (2005). Comorbidity
and pathophysiology of
obsessive-compulsive disorder
in schizophrenia: is there evi-
dence for a schizo-obsessive
subtype of schizophrenia?
J. Psychiatry Neurosci. 30,
187–193.
Bradford Hill, A. (2011). The envi-
ronment and disease: association
or causation? Bull. World Health
Organ. 83, 295–300.
Bräunig, P., Krüger, S., Shugar,
G., Höffler, J., and Börner, I.
(2000). The catatonia rating
scale I–development, reliability,
and use. Compr. Psychiatry 41,
147–158. doi: 10.1016/S0010-440X
(00)90148-2
Buckley, P. F., Miller, B. J., Lehrer,
D. S., and Castle, D. J. (2009).
Psychiatric comorbidities and
schizophrenia. Schizophr. Bull.
35, 383–402. doi: 10.1093/schbul/
sbn135
Cai, J., Zhang, W., Lu, W., Wu, Z.,
Chen, J., Yu, S., et al. (2013).
Influence of polymorphisms in
genes SLC1A1, GRIN2B, and
GRIK2 on clozapine-induced
obsessive-compulsive symptoms.
Psychopharmacology. doi: 10.1007/
s00213-013-3137-2. [Epub ahead of
print].
Canas, F., Aydinoglu, U., and Sinani, G.
(2012). Valproic acid augmentation
in clozapine-associated hand-
washing compulsion. Psychiatry
Clin. Neurosci. 66, 463–464. doi:
10.111/j.14440-1819.2012.02361.x
Catapano, F., Perris, F., Fabrazzo,
M., Cioffi, V., Giacco, D., De, S.,
et al. (2010). Obsessive-compulsive
disorder with poor insight: a
three-year prospective study.
Prog. Neuro-Psychopharmacol.
Biol. Psychiatry 34, 323–330. doi:
10.1016/j.pnpbp.2009.12.007
Chang, J. S., Ahn, Y.-M., Park, H. J.,
Lee, K. Y., Kim, S. H., Kang, U. G.,
et al. (2008). Aripiprazole augmen-
tation in clozapine-treated patients
with refractory schizophrenia:
an 8-week, randomized, double-
blind, placebo-controlled trial.
J. Clin. Psychiatry 69, 720–731. doi:
10.4088/JCP.v69n0505
Connor, K. M., Payne, V. M., Gadde,
K. M., Zhang, W., Davidson,
J. R., Connor, K. M., et al.
(2005). The use of aripiprazole
in obsessive-compulsive disorder:
preliminary observations in 8
patients. J. Clin. Psychiatry 66,
49–51. doi: 10.4088/JCP.v66n0107
Coric, V., Taskiran, S., Pittenger, C.,
Wasylink, S., Mathalon, D. H.,
Valentine, G., et al. (2005). Riluzole
augmentation in treatment-
resistant obsessive-compulsive
disorder: an open-label trial.
Biol. Psychiatry 58, 424–428. doi:
10.1016/j.biopsych.2005.04.043
Correll, C. U. (2008). Antipsychotic
polypharmacy, part 2: why
use 2 antipsychotics when 1
is not good enough? J. Clin.
Psychiatry 69, 860–861. doi:
10.4088/JCP.v69n0521
Coward, D. M. (1992). General
pharmacology of clozapine. Br. J.
Psychiatry Suppl. 17, 5–11.
Cunill, R., Castells, X., and Simeon,
D. (2009). Relationships between
obsessive-compulsive symptoma-
tology and severity of psychosis
in schizophrenia: a system-
atic review and meta-analysis.
J. Clin. Psychiatry 70, 70–82. doi:
10.4088/JCP.07r03618
de Haan, L., Beuk, N., Hoogenboom,
B., Dingemans, P., and Linszen,
D. (2002). Obsessive-compulsive
symptoms during treatment with
olanzapine and risperidone: a
prospective study of 113 patients
with recent-onset schizophre-
nia or related disorders. J. Clin.
Psychiatry 63, 104–107. doi:
10.4088/JCP.v63n0203
de Haan, L., Dudek-Hodge, C.,
Verhoeven, Y., and Denys, D. (2009).
Prevalence of psychotic disorders in
patients with obsessive-compulsive
disorder. CNS Spectr. 14,
415–417.
de Haan, L., Hoogeboom, B., Beuk,
N., Wouters, L., Dingemans,
P. M., and Linszen, D. H.
(2006). Reliability and validity
of the Yale-Brown Obsessive-
Compulsive Scale in schizophrenia
patients. Psychopharmacol. Bull. 39,
25–30.
de Haan, L., Linszen, D. H., and
Gorsira, R. (1999). Clozapine
and obsessions in patients with
recent-onset schizophrenia and
other psychotic disorders. J. Clin.
Psychiatry 60, 364–365. doi:
10.4088/JCP.v60n0603
de Haan, L., Oekeneva, A., van,
A. T., and Linszen, D. (2004).
Obsessive-compulsive disorder
and treatment with clozapine in
200 patients with recent-onset
schizophrenia or related disor-
ders. Eur. Psychiatry 19, 524. doi:
10.1016/j.eurpsy.2004.09.022
de Haan, L., Sterk, B., and van der Valk,
R. (2012). Presence of obsessive
compulsive symptoms in first-
episode schizophrenia or related
disorders is associated with subjec-
tive well-being and quality of life.
Early Interv. Psychiatry 7, 285–290.
doi: 10.1111/j.1751-7893.2012.
00377.x
de Haan, L., Sterk, B., Wouters, L., and
Linszen, D. H. (2013). The 5-year
course of obsessive-compulsive
symptoms and obsessive-
compulsive disorder in first-episode
schizophrenia and related disorders.
Schizophr. Bull. 39, 151–160. doi:
10.1093/schbul/sbr077
Deng, X., Shibata, H., Takeuchi, N.,
Rachi, S., Sakai, M., Ninomiya, H.,
et al. (2007). Association study of
polymorphisms in the glutamate
transporter genes SLC1A1, SLC1A3,
and SLC1A6 with schizophrenia.
Am. J. Med. Genet. 144B, 271–278.
doi: 10.1002/ajmg.b.30351
DeVylder, J. E., Oh, A. J., Ben-David,
S., Azimov, N., Harkavy-Friedman,
J. M., and Corcoran, C. M. (2012).
Obsessive compulsive symptoms in
individuals at clinical risk for psy-
chosis: Association with depressive
symptoms and suicidal ideation.
Schizophrenia Res. 140, 110–113.
doi: 10.1016/j.schres.2012.07.009
Dickel, D. E., Veenstra-VanderWeele,
J., Cox, N. J., Wu, X., Fischer, D.
J., Van Etten-Lee, M., et al. (2006).
Association testing of the positional
and functional candidate gene
SLC1A1/EAAC1 in early-onset
obsessive-compulsive disorder.
Arch. Gen. Psychiatry 63, 778–785.
doi: 10.1001/archpsyc.63.7.778
Dold, M., Aigner, M., Lanzenberger, R.,
and Kasper, S. (2011). Efficacy of
antipsychotic augmentation therapy
in treatment-resistant obsessive-
compulsive disorder a meta-analysis
of double-blind, randomised,
placebo-controlled trials. Fortschr.
Neurol. Psychiatr. 79, 453–466. doi:
10.1055/s-0031-1273397
Dowling, F. G., Pato, M. T., and Pato,
C. N. (1995). Comorbidity of
obsessive-compulsive and psy-
chotic symptoms: a review. Harv.
Rev. Psychiatry 3, 75–83. doi:
10.3109/10673229509017170
Duggan, L., Fenton, M., Dardennes, R.
M., El-Dosoky, A., and Indran, S.
(2000). Olanzapine for schizophre-
nia. Cochrane Database Syst.
Rev. 2:CD001359. doi: 10.1002/
14651858.CD001359
Ebel, H., Gross, G., Klosterkotter,
J., Huber, G., Ebel, H., Gross,
G., et al. (1989). Basic symp-
toms in schizophrenic and affec-
tive psychoses. Psychopathology 22,
224–232. doi: 10.1159/000284602
Emmelkamp, P. M. G., and van Oppen,
P. (2000). Zwangsstoerungen.
Göttingen: Hogrefe.
Englisch, S., Esslinger, C., Inta,
D., Weinbrenner, A., Peus, V.,
Gutschalk, A., et al. (2009).
Clozapine-induced obsessive com-
pulsive syndromes improve in
combination with aripiprazole.
Clin. Neuropharmacol. 32, 227–229.
doi: 10.1097/WNF.0b013e31819
cc8e6
Englisch, S., and Zink, M. (2008).
Combined antipsychotic treatment
involving clozapine and aripipra-
zole. Prog. Neuropsychopharmacol.
Frontiers in Pharmacology | Neuropharmacology August 2013 | Volume 4 | Article 99 | 10
Schirmbeck and Zink Obsessions and compulsions in schizophrenia
Biol. Psychiatry 32, 1386–1392. doi:
10.1016/j.pnpbp.2008.02.010
Ertugrul, A., nil Yagcioglu, A. E.,
Eni, N., and Yazici, K. M.
(2005). Obsessive-compulsive
symptoms in clozapine-treated
schizophrenic patients. Psychiatry
Clin. Neurosci. 59, 219–222. doi:
10.1111/j.1440-1819.2005.01362.x
Fenton, W. S., and McGlashan, T. H.
(1986). The prognostic significance
of obsessive-compulsive symptoms
in schizophrenia. Am. J. Psychiatry
143, 437–441.
Fink, M., and Taylor, M. A. (2001).
The many varieties of catato-
nia. Eur. Arch. Psychiatry Clin.
Neurosci. 251(Suppl. 1), I8–13. doi:
10.1007/PL00014200
Fink, M. (2013). Rediscovering catato-
nia: the biography of a treatable syn-
drome. Acta Psychiatr. Scand. Suppl.
127, 1–47. doi: 10.1111/acps.12038
Foerstner, U., Anne Marie, K., and
Ulrich, V. (2011). Störungsspezifische
Behandlung der Zwangsstörungen:
Ein Therapiemanual. Stuttgart:
Kohlhammer.
Fontenelle, L. F., Lin, A., Pantelis, C.,
Wood, S. J., Nelson, B., and Yung, A.
R. (2012). Markers of vulnerability
to obsessive-compulsive disorder in
an ultra-high risk sample of patients
who developed psychosis. Early
Interv. Psychiatry 6, 201–206. doi:
10.1111/j.1751-7893.2012.00357.x
Fontenelle, L. F., Lin, A., Pantelis,
C., Wood, S. J., Nelson, B.,
and Yung, A. R. (2011). A
longitudinal study of obsessive-
compulsive disorder in individuals
at ultra-high risk for psychosis.
J. Psychiatr. Res. 45, 1140–1145. doi:
10.1016/j.jpsychires.2011.03.005
Friedlander, L., and Desrocher, M.
(2006). Neuroimaging studies
of obsessive-compulsive disor-
der in adults and children. Clin.
Psychol. Rev. 26, 32–49. doi:
10.1016/j.cpr.2005.06.010
Fusar-Poli, P., Nelson, B., Valmaggia,
L., Yung, A. R., and McGuire, P.
K. (2012). Comorbid depressive and
anxiety disorders in 509 individuals
with an at-risk mental state: impact
on psychopathology and transi-
tion to psychosis. Schizophr. Bull.
doi: 10.1093/schbul/sbs136. [Epub
ahead of print].
Gava, I., Barbui, C., Aguglia, E.,
Carlino, D., Churchill, R., De, V. M.,
et al. (2007). Psychological treat-
ments versus treatment as usual
for obsessive compulsive disorder
(OCD). Cochrane Database Syst.
Rev. 2:CD005333. doi: 10.1002/
14651858.CD005333.pub2
Gregory, A., Lau, J., and Eley, T.
(2008). Finding gene-environment
interactions for generalised anxi-
ety disorder. Eur. Arch. Psychiatry
Clin. Neurosci. 258, 69–75. doi:
10.1007/s00406-007-0785-4
Gross-Isseroff, R., Hermesh, H.,
Zohar, J., and Weizman, A. (2003).
Neuroimaging communality
between schizophrenia and obses-
sive compulsive disorder: a putative
basis for schizo-obsessive disorder?
World J. Biol. Psychiatry 4, 129–134.
doi: 10.1080/15622970310029907
Guillem, F., Satterthwaite, J.,
Pampoulova, T., and Stip, E.
(2009). Relationship between
psychotic and obsessive compul-
sive symptoms in schizophrenia.
Schizophr. Res. 115, 358–362. doi:
10.1016/j.schres.2009.06.004
Gupta, S., and Daniel, D. G. (1995).
Cautions in the clozapine-
to-risperidone switch. Ann.
Clin. Psychiatry 7, 149. doi:
10.3109/10401239509149043
Hadi, E., Greenberg, Y., and Sirota,
P. (2011). Obsessive-compulsive
symptoms in schizophrenia:
arevalence, clinical features and
treatment. a literature review.World
J. Biol. Psychiatry 13, 2–13. doi:
10.3109/15622975.2011.559271
Hashim, H. M., Fawzy, N., Fawzi,
M. M., and Karam, R. A. (2012).
Brain-derived neurotrophic fac-
tor Val66Met polymorphism
and obsessive-compulsive symp-
toms in Egyptian schizophrenia
patients. J. Psychiatr. Res. 46,
762–766. doi: 10.1016/j.jpsychires.
2012.03.007
Hermesh, H., Weizman, A., Gur, S.,
Zalsman, G., Shiloh, R., Zohar, J.,
et al. (2003). Alternation learning
in OCD/schizophrenia patients.
Eur. Neuropsychopharmacol.
13, 87–91. doi: 10.1016/S0924-
977X(02)00128-1
Hippius, H. (1989). The history of
clozapine. Psychopharmacology
99(Suppl.), S3–S5. doi: 10.1007/
BF00442551
Hur, J. W., Shin, N. Y., Jang, J. H., Shim,
G., Park, H. Y., Hwang, J. Y., et al.
(2012). Clinical and neurocognitive
profiles of subjects at high risk
for psychosis with and without
obsessive-compulsive symptoms.
Aust. N.Z. J. Psychiatry 46, 161–169.
doi: 10.1177/0004867411432851
Hwang, M. Y., Kim, S. W., Yum,
S. Y., and Opler, L. A. (2009).
Management of schizophrenia
with obsessive-compulsive features.
Psychiatr. Clin. North Am. 32,
835–851. doi: 10.1016/j.psc.2009.
08.002
Hwang, M. Y., Morgan, J. E., and
Losconzcy, M. F. (2000). Clinical
and neuropsychological profiles of
obsessive-compulsive schizophre-
nia: a pilot study. J. Neuropsychiatry
Clin. Neurosci. 12, 91–94.
Joel, D. (2006). Current animal
models of obsessive compul-
sive disorder: a critical review.
Prog. Neuropsychopharmacol.
Biol. Psychiatry 30, 374–388. doi:
10.1016/j.pnpbp.2005.11.006
Joober, R., and Boksa, P. (2010).
Clozapine: a distinct, poorly under-
stood and under-used molecule.
J. Psychiatry Neurosci. 35, 147–149.
doi: 10.1503/jpn.100055
Kane, J., Honigfeld, G., Singer, J., and
Meltzer, H. (1988). Clozapine
for the treatment-resistant
schizophrenic. a double-blind
comparison with chlorpromazine.
Arch. Gen. Psychiatry 45, 789–796.
doi: 10.1001/archpsyc.1988.01800
330013001
Kane, J. M. (2011). A user’s guide
to clozapine. Acta Psychiatr. Scand.
123, 407–408. doi: 10.1111/j.1600-
0447.2011.01711.x
Kang, X., and Simpson, G. M. (2010).
Clozapine: more side effects but
still the best antipsychotic. J. Clin.
Psychiatry 71, 982–983. doi:
10.4088/JCP.09com05497yel
Keers, R., and Uher, R. (2012). Gene-
environment interaction in major
depression and antidepressant treat-
ment response. Curr. Psychiatry Rep.
14, 129–137. doi: 10.1007/s11920-
011-0251-x
Kelly, D. L., Richardson, C. M.,
Tamminga, C. A., and Carpenter,
W. T. (2003). The efficacy of high-
dose olanzapine versus clozapine
in treatment-resistant schizophre-
nia: a double-blind, crossover
study. J. Clin. Psychopharmacol.
23, 668–670. doi: 10.1097/01.jcp.
0000096246.29231.73
Kim, S. W., Shin, I. S., Kim, J. M.,
Yang, S. J., Hwang, M. Y., and
Yoon, J. S. (2008). Amisulpride
improves obsessive-compulsive
symptoms in schizophrenia patients
taking atypical antipsychotics: an
open-label switch study. J. Clin.
Psychopharmacol. 28, 349–352. doi:
10.1097/JCP.0b013e318172755a
Koran, L. M., Hanna, G. L., Hollander,
E., Nestadt, G., Simpson, H. B., and
American Psychiatric Association.
(2007). Practice guideline for
the treatment of patients with
obsessive-compulsive disorder. Am.
J. Psychiatry 164, 5–53.
Kuelz, A. K., Hohagen, F.,
and Voderholzer, U. (2004).
Neuropsychological performance
in obsessive-compulsive disorder:
a critical review. Biol. Psychol. 65,
185–236. doi: 10.1016/j.biopsycho.
2003.07.007
Kuelz, A. K., and Voderholzer, U.
(2011). Psychotherapie der
Zwangsstörung. Der Nervenarzt
82, 308–318. doi: 10.1007/s00115-
010-2962-3
Kumbhani, S. R., Roth, R. M.,
Kruck, C. L., Flashman, L. A.,
and McAllister, T. W. (2010).
Nonclinical obsessive-compulsive
symptoms and executive functions
in schizophrenia. J. Neuropsychiatry
Clin. Neurosci. 22, 304–312. doi:
10.1176/appi.neuropsych.22.3.304
Kwon, J. S., Jang, J. H., Choi, J. S., and
Kang, D. H. (2009a). Neuroimaging
in obsessive-compulsive disorder.
Expert Rev. Neurother. 9, 255–269.
doi: 10.1586/14737175.9.2.255
Kwon, J. S., Joo, Y. H., Nam, H. J.,
Lim, M., Cho, E. Y., Jung, M. H.,
et al. (2009b). Association of the
glutamate transporter gene SLC1A1
with atypical antipsychotics-
induced obsessive-compulsive
symptoms. Arch. Gen. Psychiatry
66, 1233–1241. doi: 10.1001/arch-
genpsychiatry.2009.155
Lafleur, D. L., Pittenger, C., Kelmendi,
B., Gardner, T., Wasylink, S.,
Malison, R. T., et al. (2006). N-
acetylcysteine augmentation in
serotonin reuptake inhibitor refrac-
tory obsessive-compulsive disorder.
Psychopharmacology 184, 254–256.
doi: 10.1007/s00213-005-0246-6
Lakatos, A., and Reinecker, H. (2007).
Kognitive Verhaltenstherapie bei
Zwangsstörungen: Ein Therapie-
manual. Göttingen: Hogrefe.
Lee, M.-J., Shin, Y.-B., Sunwoo, Y.-K.,
Jung, S.-H., Kim, W.-H., Kang,
M.-H., et al. (2009). Comparative
analysis of cognitive function in
schizophrenia with and without
obsessive compulsive disorder.
Psychiatry Invest. 6, 286–293. doi:
10.4306/pi.2009.6.4.286
Lim, M., Park, D. Y., Kwon, J. S.,
Joo, Y. H., and Hong, K. S.
(2007). Prevalence and clinical
characteristics of obsessive-
compulsive symptoms associated
with atypical antipsychotics.
J. Clin. Psychopharmacol. 27,
712–713. doi: 10.1097/JCP.0b013
e31815a584c
Lin, S. K., Su, S. F., and Pan, C. H.
(2006). Higher plasma drug con-
centration in clozapine-treated
schizophrenic patients with side
effects of obsessive/compulsive
symptoms. Ther. Drug Monit.
28, 303–307. doi: 10.1097/01.ftd.
0000211801.66569.80
Linden, D. E. (2006). How psychother-
apy changes the brain - the contri-
bution of functional neuroimaging.
Mol. Psychiatry 11, 528–538. doi:
10.1038/sj.mp.4001816
www.frontiersin.org August 2013 | Volume 4 | Article 99 | 11
Schirmbeck and Zink Obsessions and compulsions in schizophrenia
Lopez-Gil, X., Artigas, F., and Adell,
A. (2010). Unraveling monoamine
receptors involved in the action of
typical and atypical antipsychotics
on glutamatergic and serotonergic
transmission in prefrontal cortex.
Curr. Pharm. Des. 16, 502–515. doi:
10.2174/138161210790361416
Lykouras, L., Alevizos, B.,
Michalopoulou, P., and Rabavilas,
A. (2003). Obsessive-compulsive
symptoms induced by atypi-
cal antipsychotics: a review of
the reported cases. Prog. Neuro-
psychopharmacol. Biol. Psychiatry
27, 333–346. doi: 10.1016/S0278-
5846(03)00039-3
Lysaker, P. H., Lancaster, R. S., Nees, M.
A., and Davis, L. W. (2004). Patterns
of obsessive-compulsive symptoms
and social function in schizophre-
nia. Psychiatry Res. 125, 139–146.
doi: 10.1016/j.psychres.2003.12.007
Lysaker, P. H., and Whitney, K. A.
(2009). Obsessive-compulsive
symptoms in schizophrenia: preva-
lence, correlates and treatment.
Expert Rev. Neurother. 9, 99–107.
doi: 10.1586/14737175.9.1.99
Lysaker, P. H., Whitney, K. A., and
Davis, L. W. (2009). Associations
of executive function with con-
current and prospective reports of
obsessive-compulsive symptoms in
schizophrenia. J. Neuropsychiatry
Clin. Neurosci. 21, 38–42. doi:
10.1176/appi.neuropsych.21.1.38
Lysaker, P. H., Bryson, G. J., Marks,
K. A., Greig, T. C., and Bell, M.
D. (2002). Association of obsessions
and compulsions in schizophre-
nia with neurocognition and neg-
ative symptoms. J. Neuropsychiatry
Clin. Neurosci. 14, 449–453. doi:
10.1176/appi.neuropsych.14.4.449
Mahasuar, R., Janardhan Reddy, Y. C.,
and Math, S. B. (2011). Obsessive-
compulsive disorder with and
without bipolar disorder. Psychiatry
Clin. Neurosci. 65, 423–433. doi:
10.1111/j.1440-1819.2011.02247.x
McEvoy, J. P., Lieberman, J. A.,
Stroup, T. S., Davis, S. M., Meltzer,
H. Y., Rosenheck, R. A., et al.
(2006). Effectiveness of clozapine
versus olanzapine, quetiapine,
and risperidone in patients with
chronic schizophrenia who did
not respond to prior atypical
antipsychotic treatment. Am. J.
Psychiatry 163, 600–610. doi:
10.1176/appi.ajp.163.4.600
Meijer, J. H. M., Swets, M. M., Keeman,
S. M., Nieman, D. H. P., Meijer,
C. J. P., and GROUP, I. (2013). Is
a schizo-obsessive subtype associ-
ated with cognitive impairment?
Results from a large cross-sectional
study in patients with psychosis
and their unaffected relatives.
J. Nerv. Ment. Dis. 201, 30–35. doi:
10.1097/NMD.0b013e31827ab2b2
Meltzer, H. Y. (1995). Role of sero-
tonin in the action of atypical
antipsychotic drugs. Clin. Neurosci.
3, 64–75.
Meltzer, H. Y. (1994). An overview
of the mechanism of action of
clozapine. J. Clin. Psychiatry 55,
47–52.
Meltzer, H. Y., and Huang, M. (2008).
In vivo actions of atypical antipsy-
chotic drug on serotonergic and
dopaminergic systems. Prog.
Brain Res. 172, 177–197. doi:
10.1016/S0079-6123(08)00909-6
Meltzer, H. Y., Li, Z., Kaneda, Y.,
and Ichikawa, J. (2003). Serotonin
receptors: their key role in drugs
to treat schizophrenia. Prog.
Neuropsychopharmacol. Biol.
Psychiatry 27, 1159–1172. doi:
10.1016/j.pnpbp.2003.09.010
Meltzer, H. Y., and Sumiyoshi, T.
(2008). Does stimulation of
5-HT(1A) receptors improve cog-
nition in schizophrenia? Behav.
Brain Res. 195, 98–102. doi:
10.1016/j.bbr.2008.05.016
Meltzer, H. Y. (2012). Clozapine.
Clin. Schizophr. Relat. Psychoses 6,
134–144. doi: 10.3371/CSRP.6.3.5
Menzies, L., Chamberlain, S. R., Laird,
A. R., Thelen, S. M., Sahakian,
B. J., and Bullmore, E. T. (2008).
Integrating evidence from neu-
roimaging and neuropsychological
studies of obsessive-compulsive
disorder: the orbitofronto-
striatal model revisited. Neurosci.
Biobehav. Rev. 32, 525–549. doi:
10.1016/j.neubiorev.2007.09.005
Mukhopadhaya, K., Krishnaiah, R.,
Taye, T., Nigam, A., Bailey, A. J.,
Sivakumaran, T., et al. (2009).
Obsessive-compulsive disorder in
UK clozapine-treated schizophre-
nia and schizoaffective disorder:
a cause for clinical concern.
J. Psychopharmacol. 23, 6–13. doi:
10.1177/0269881108089582
Murphy, D. L., Timpano, K. R.,
Wheaton, M. G., Greenberg, B.
D., and Miguel, E. C. (2010).
Obsessive-compulsive disorder and
its related disorders: a reappraisal
of obsessive-compulsive spectrum
concepts. Dialogues Clin. Neurosci.
12. 131–148.
Muscatello, M. R., Bruno, A., Pandolfo,
G., Mico, U., Scimeca, G., Romeo,
V. M., et al. (2011). Effect of
aripiprazole augmentation of
serotonin reuptake inhibitors
or clomipramine in treatment-
resistant obsessive-compulsive
disorder: a double-blind,
placebo-controlled study. J. Clin.
Psychopharmacol. 31, 174–179. doi:
10.1097/JCP.0b013e31820e3db6
Nicolini, H., Arnold, P., Nestadt, G.,
Lanzagorta, N., and Kennedy, J.
L. (2009). Overview of genetics
and obsessive-compulsive disorder.
Psychiatry Res. 170, 7–14. doi:
10.1016/j.psychres.2008.10.011
Niendam, T. A., Berzak, J., Cannon,
T. D., and Bearden, C. E. (2009).
Obsessive compulsive symptoms in
the psychosis prodrome: correlates
of clinical and functional outcome.
Schizophrenia Res. 108, 170–175.
doi: 10.1016/j.schres.2008.11.023
Nolfe, G., Milano, W., Zontini,
G., Petrella, C., De, R. M.,
Rundle-Smith, S., et al. (2010).
Obsessive-compulsive symptoms
in schizophrenia: their relationship
with clinical features and phar-
macological treatment. J. Psychiat.
Pract. 16, 235–242. doi: 10.1097/
01.pra.0000386909.84289.ee
Nugent, N., Tyrka, A., Carpenter,
L., and Price, L. (2011). Gene-
environment interactions: early
life stress and risk for depres-
sive and anxiety disorders.
Psychopharmacology 214, 175–196.
doi: 10.1007/s00213-010-2151-x
Oelkers, C., Martin, H., and Miriam,
B. (2007). Zwangsst+Ârungen:
Ein kognitiv-verhaltensther
apeutisches Behandlungsmanual.
Weinheim: Beltz Psychologie
Verlags Union.
Öngür, D., and Goff, D. C. (2005).
Obsessive-compulsive symp-
toms in schizophrenia: associated
clinical features, cognitive func-
tion and medication status.
Schizophr. Res. 75, 349–362.
doi: 10.1016/j.schres.2004.08.012
Pani, L., Villagran, J. M., Kontaxakis,
V. P., and Alptekin, K. (2008).
Practical issues with amisulpride in
the management of patients with
schizophrenia. Clin. Drug Invest. 28,
465–477. doi: 10.2165/00044011-
200828080-00001
Patel, D. D., Laws, K. R., Padhi, A.,
Farrow, J. M., Mukhopadhaya,
K., Krishnaiah, R., et al. (2010).
The neuropsychology of the
schizo-obsessive subtype of
schizophrenia: a new analysis.
Psychol. Med. 40, 921–933. doi:
10.1017/S0033291709991255
Pauls, D. L. (2010). The genetics
of obsessive-compulsive disorder: a
review. Dialogues Clin. Neurosci. 12,
149–163.
Peters, B., and de, H. L. (2009).
Remission of schizophrenia psy-
chosis and strong reduction of
obsessive-compulsive disorder after
adding clozapine to aripiprazole.
Prog. Neuro-Psychopharmacol. Biol.
Psychiatry 33, 1576–1577. doi:
10.1016/j.pnpbp.2009.09.013
Pittenger, C., Krystal, J. H., and Coric,
V. (2006). Glutamate-modulating
drugs as novel pharmacothera-
peutic agents in the treatment
of obsessive-compulsive dis-
order. NeuroRx 3, 69–81. doi:
10.1016/j.nurx.2005.12.006
Pogarell, O., Hamann, C., Poepperl,
G., Juckel, G., Chouker, M.,
Zaudig, M., et al. (2003). Elevated
brain serotonin transporter
availability in patients with
obsessive-compulsive disorder.
Biol. Psychiatry 54, 1406–1413. doi:
10.1016/S0006-3223(03)00183-5
Poyurovsky, M. (2013). Schizoobsessive
Disorder, Vol. 1. Cambridge
University Press, 1–245. ISBN: 1107
000122.
Poyurovsky, M., Faragian, S.,
Kleinman-Balush, V., Pashinian, A.,
Kurs, R., and Fuchs, C. (2007a).
Awareness of illness and insight
into obsessive-compulsive symp-
toms in schizophrenia patients
with obsessive-compulsive disorder.
J. Nervous MentalDis. 195, 765–768.
doi: 10.1097/NMD.0b013e318142
ce67
Poyurovsky, M., Faragian, S., Pashinian,
A., Levi, A., Viosbrod, A., Stryjer,
R., et al. (2007b). Neurological
soft signs in schizophrenia patients
with obsessive-compulsive dis-
order. J. Neuropsychiat. Clin.
Neurosci. 19, 145–150. doi:
10.1176/appi.neuropsych.19.2.145
Poyurovsky, M., Faragian, S.,
Pashinian, A., Heidrach, L.,
Fuchs, C., Weizman, R., et al.
(2008). Clinical characteristics
of schizotypal-related obsessive-
compulsive disorder. Psychiatry
Res. 159, 254–258. doi: 10.1016/
j.psychres.2007.02.019
Poyurovsky, M., Fuchs, C., and
Weizman, A. (1999a). Obsessive-
compulsive disorder in patients
with first-episode schizophrenia.
Am. J. Psychiatry 156, 1998–2000.
Poyurovsky, M., Isakov, V., Hromnikov,
S., Modai, I., Rauchberger, B.,
Schneidman, M., et al. (1999b).
Fluvoxamine treatment of obses-
sivecompulsive symptoms in
schizophrenic patients: an
add-on open study. Int. Clin.
Psychopharmacol. 14, 95–100.
doi: 10.1097/00004850-199903000-
00006
Poyurovsky, M., Glick, I., and Koran,
L. M. (2010). Lamotrigine aug-
mentation in schizophrenia and
schizoaffective patients with
obsessive-compulsive symptoms.
J. Psychopharmacol. 24, 861–866.
doi: 10.1177/0269881108099215
Frontiers in Pharmacology | Neuropharmacology August 2013 | Volume 4 | Article 99 | 12
Schirmbeck and Zink Obsessions and compulsions in schizophrenia
Poyurovsky, M., and Koran, L. M.
(2005). Obsessive-compulsive
disorder (OCD) with schizo-
typy vs. schizophrenia with
OCD: diagnostic dilemmas
and therapeutic implications.
J. Psychiatr. Res. 39, 399–408. doi:
10.1016/j.jpsychires.2004.09.004
Poyurovsky, M., Weizman, A.,
and Weizman, R. (2004).
Obsessive-compulsive disorder
in schizophrenia: clinical character-
istics and treatment. CNS Drugs 18,
989–1010. doi: 10.2165/00023210-
200418140-00004
Poyurovsky, M., Weizman, R.,
Weizman, A., Koran, L.,
Poyurovsky, M., Weizman, R.,
et al. (2005). Memantine for
treatment-resistant OCD. Am. J.
Psychiatry 162, 2191–2192. doi:
10.1176/appi.ajp.162.11.2191-a
Poyurovsky, M., Zohar, J., Glick,
I., Koran, L. M., Weizman,
R., Tandon, R., et al. (2012).
Obsessive-compulsive symptoms
in schizophrenia: implications for
future psychiatric classifications.
Comp. Psychiatry 53, 480–483. doi:
10.1016/j.comppsych.2011.08.009
Rajender, G., Bhatia, M. S., Kanwal,
K., Malhotra, S., Singh, T. B., and
Chaudhary, D. (2011). Study of
neurocognitive endophenotypes in
drug-naive obsessive-compulsive
disorder patients, their first-
degree relatives and healthy
controls. Acta Psychiatr. Scand.
124, 152–161. doi: 10.1111/
j.1600-0447.2011.01733.x
Remington, G. (2008). Alterations of
dopamine and serotonin trans-
mission in schizophrenia. Prog.
Brain Res. 172, 117–140. doi:
10.1016/S0079-6123(08)00906-0
Reznik, I., Kotler, M., and Weizman,
A. (2005). Obsessive and compul-
sive symptoms in schizophrenia
patients–from neuropsychology
to clinical typology and clas-
sification. J. Neuropsychiatry
Clin. Neurosci. 17, 254–255. doi:
10.1176/appi.neuropsych.17.2.254
Reznik, I., Mester, R., Kotler, M.,
and Weizman, A. (2001). Obsessive-
compulsive schizophrenia: a new
diagnostic entity? J. Neuropsychiatry
Clin. Neurosci. 13, 115–116. doi:
10.1176/appi.neuropsych.13.1.115
Reznik, I., Yavin, I., Stryjer, R., Spivak,
B., Gonen, N., Strous, R., et al.
(2004). Clozapine in the treatment
of obsessive-compulsive symptoms
in schizophrenia patients: a case
series study. Pharmacopsychiatry 37,
52–56. doi: 10.1055/s-2004-815525
Reznik, I. M., and Sirota, P. M. M.
P. (2000). Obsessive and compul-
sive symptoms in schizophrenia:
a randomized controlled trial
with fluvoxamine and neurolep-
tics. J. Clin. Psychopharmacol. 20,
410–416. doi: 10.1097/00004714-
200008000-00004
Rocha, F. L., and Hara, C. (2006).
Benefits of combining aripiprazole
to clozapine: three case reports.
Prog. Neuropsychopharmacol. Biol.
Psychiatry 30, 1167–1169. doi:
10.1016/j.pnpbp.2006.03.024
Rodriguez, C. I., Corcoran, C., and
Simpson, H. B. (2010). Diagnosis
and treatment of a patient with
both psychotic and obsessive-
compulsive symptoms. Am. J.
Psychiatry 167, 754–761. doi:
10.1176/appi.ajp.2009.09070997
Rosa-Alcazar, A. I., Sanchez-Meca, J.,
Gomez-Conesa, A., and Marin-
Martinez, F. (2008). Psychological
treatment of obsessive-compulsive
disorder: a meta-analysis. Clin.
Psychol. Rev. 28, 1310–1325. doi:
10.1016/j.cpr.2008.07.001
Rubino, I. A., Frank, E., Croce,
N. R., Pozzi, D., Lanza di, S.
T., and Siracusano, A. (2009).
A comparative study of axis I
antecedents before age 18 of unipo-
lar depression, bipolar disorder and
schizophrenia. Psychopathology 42,
325–332. doi: 10.1159/000232975
Ryu, S., Oh, S., Cho, E. Y., Nam, H. J.,
Yoo, J. H., Park, T., et al. (2011).
Interaction between genetic variants
of DLGAP3 and SLC1A1 affecting
the risk of atypical antipsychotics-
induced obsessive-compulsive
symptoms. Am. J. Med. Genet. 156,
949–959. doi: 10.1002/ajmg.b.31242
Sa, A. R., Hounie, A. G., Sampaio,
A. S., Arrais, J., Miguel, E. C.,
and Elkis, H. (2009). Obsessive-
compulsive symptoms and disorder
in patients with schizophre-
nia treated with clozapine or
haloperidol. Compr. Psychiatry 50,
437–442. doi: 10.1016/j.comppsych.
2008.11.005
Saxena, S., Gorbis, E., O’Neill, J.,
Baker, S. K., Mandelkern, M. A.,
Maidment, K. M., et al. (2009).
Rapid effects of brief intensive
cognitive-behavioral therapy on
brain glucose metabolism in
obsessive-compulsive disorder.
Mol. Psychiatry 14, 197. doi:
10.1038/sj.mp.4002134
Scatton, B., Claustre, Y., Cudennec,
A., Oblin, A., Perrault, G., Sanger,
D. J., et al. (1997). Amisulpride:
from animal pharmacology to
therapeutic action. Int. Clin.
Psychopharmacol. 12, S29–S36.
doi: 10.1097/00004850-199705002-
00006
Schirmbeck, F., Esslinger, C., Rausch,
F., Englisch, S., Meyer-Lindenberg,
A., and Zink, M. (2011).
Antiserotonergic antipsychotics
are associated with obsessive-
compulsive symptoms in
schizophrenia. Psychol. Med.
41, 2361–2374. doi: 10.1017/S003
3291711000419
Schirmbeck, F., Nieratschker, V.,
Frank, J., Englisch, S., Rausch,
F., Meyer-Lindenberg, A., et al.
(2012a). Polymorphisms in
the glutamate transporter gene
SLC1A1 and obsessive compulsive
symptoms induced by second
generation antipsychotic agents.
Psychiatr. Genet. 22, 245–252. doi:
10.1097/YPG.0b013e328353fbee
Schirmbeck, F., Rausch, F., Englisch,
S., Eifler, S., Esslinger, C., Meyer-
Lindenberg, A., et al. (2012b). Stable
cognitive deficits in schizophrenia
patients with comorbid obsessive-
compulsive symptoms: a 12 months
longitudinal study. Schizophr. Bull.
doi: 10.1093/schbul/sbs123. [Epub
ahead of print].
Schirmbeck, F., and Zink, M. (2012).
Clozapine-induced obsessive-
compulsive symptoms in
schizophrenia: a critical review.
Curr. Neuropharmacol. 10, 88–95.
doi: 10.2174/157015912799362724
Schirmbeck, F., Rausch, F., Englisch,
S., Eifler, S., Esslinger, C.,
Meyer-Lindenberg, A., et al.
(2013). Differential effects
of antipsychotic agents on
obsessive-compulsive symptoms in
schizophrenia: a longitudinal study.
J. Psychopharmacol. 27, 349–357.
doi: 10.1177/0269881112463470
Schirmbeck, F., and Zink, M. (2013).
“Obsessive-compulsive syndromes
in schizophrenia: a case for
polypharmacy?” in Polypharmacy in
Psychiatric Practice, ed M. Ritsner
(Dordrecht; Heidelberg; New York;
London: Springer), 233–261.
Sevincok, L., Akoglu, A., and Arslantas,
H. (2006). Schizo-obsessive and
obsessive-compulsive disorder:
comparison of clinical character-
istics and neurological soft signs.
Psychiatry Res. 145, 241–248. doi:
10.1016/j.psychres.2005.11.010
Shapiro, D. A., Renock, S., Arrington,
E., Chiodo, L. A., Liu, L. X., Sibley,
D. R., et al. (2003). Aripiprazole, a
novel atypical antipsychotic drug
with a unique and robust pharma-
cology. Neuropsychopharmacology
28, 1400–1411. doi: 10.1038/sj.npp.
1300203
Shioiri, T., Shinada, K., Kuwabara,
H., and, Someya, T. (2007).
Early prodromal symptoms
and diagnoses before first psy-
chotic episode in 219 inpatients
with schizophrenia. Psychiatry
Clin. Neurosci. 61, 348–354. doi:
10.1111/j.1440-1819.2007.01685.x
Shugart, Y. Y., Wang, Y., Samuels, J.
F., Grados, M. A., Greenberg, B.
D., Knowles, J. A., et al. (2009).
A family-based association study
of the glutamate transporter gene
SLC1A1 in obsessive-compulsive
disorder in 378 families. Am. J. Med.
Genet. B Neuropsychiatr. Genet.
150B, 886–892. doi: 10.1002/ajmg.
b.30914
Starck, G., Ljungberg, M., Nilsson, M.,
Jonsson, L., Lundberg, S., Ivarsson,
T., et al. (2008). A 1H magnetic res-
onance spectroscopy study in adults
with obsessive compulsive disorder:
relationship between metabolite
concentrations and symptom sever-
ity. J. Neural Trans. 115, 1051–1062.
doi: 10.1007/s00702-008-0045-4
Steingard, S., Chengappa, K. N.
R., Baker, R., and, Schooler, N.
R. (1993). Clozapine, obsessive
symptoms, and serotonergic mech-
anisms. Am. J. Psychiatry 150,
1435.
Stengel, E. (1945). A study on some
clinical aspects of the relationship
between obsessional neurosis and
psychotic reaction types. J. Ment.
Sci. 91, 166–187.
Sterk, B., Lankreijer, K., Linszen, D. H.,
and de, Haan, L. (2011). Obsessive-
compulsive symptoms in first
episode psychosis and in subjects
at ultra high risk for developing
psychosis, onset and relationship
to psychotic symptoms. Aust. N.Z.
J. Psychiatry 45, 400–405. doi:
10.3109/00048674.2010.533363
Stewart, S. E., Fagerness, J. A., Platko,
J., Smoller, J. W., Scharf, J.
M., Illmann, C., et al. (2007).
Association of the SLC1A1 glu-
tamate transporter gene and
obsessive-compulsive disorder. Am.
J. Med. Genet. 144 B, 1027–1033.
doi: 10.1002/ajmg.b.30533
Still, D. J., Dorson, P. G., Crismon,
M. L., and, Pousson, C. (1996).
Effects of switching inpa-
tients with treatment-resistant
schizophrenia from clozapine to
risperidone. Psychiatr. Serv. 47,
1382–1384.
Sullwold, L., and Huber, G. (1986).
Basic schizophrenic disorders.
Monogr. Gesamtgeb. Psychiatr.
Psychiatry Ser. 42, 1–177. doi:
10.1007/978-3-642-82842-3
Tiihonen, J., Lonnqvist, J., Wahlbeck,
K., Klaukka, T., Niskanen, L.,
Tanskanen, A., et al. (2009). 11-year
follow-up of mortality in patients
with schizophrenia: a population-
based cohort study (FIN11
study). Lancet 374, 620–627. doi:
10.1016/S0140-6736(09)60742-X
www.frontiersin.org August 2013 | Volume 4 | Article 99 | 13
Schirmbeck and Zink Obsessions and compulsions in schizophrenia
Tiryaki, A., and Ozkorumak, E.
(2010). Do the obsessive-
compulsive symptoms have an
effect in schizophrenia? Compr.
Psychiatry 51, 357–362. doi:
10.1016/j.comppsych.2009.10.007
Tumkaya, S., Karadag, F., Oguzhanoglu,
N. K., Tekkanat, C., Varma,
G., Ozdel, O., et al. (2009).
Schizophrenia with obsessive-
compulsive disorder and
obsessive-compulsive disorder
with poor insight: a neuropsycho-
logical comparison. Psychiatry Res.
165, 38–46. doi: 10.1016/j.psychres.
2007.07.031
Tundo, A., Salvati, L., Di Spigno, D.,
Cieri, L., Parena, A., Necci, R.,
et al. (2012). Cognitive-behavioral
therapy for obsessive-compulsive
disorder as a comorbidity with
schizophrenia or schizoaffective dis-
order. Psychother. Psychosom. 81,
58–60. doi: 10.1159/000329455
Van Dael, F., van, Os, J., de Graaf,
R., ten Have, M., Krabbendam,
L., and Myin-Germeys, I. (2011).
Can obsessions drive you mad?
Longitudinal evidence that
obsessive-compulsive symptoms
worsen the outcome of early psy-
chotic experiences. Acta Psychiatr.
Scand. 123, 136–146. doi: 10.1111/
j.1600-0447.2010.01609.x
Van der Wee, N. J., Stevens, H.,
Hardeman, J. A., Mandl, R.
C., Denys, D. A., van Megen,
H. J., et al. (2004). Enhanced
dopamine transporter density in
psychotropic-naive patients with
obsessive-compulsive disorder
shown by [123I]β-CIT SPECT. Am.
J. Psychiatry 161, 2201–2206. doi:
10.1176/appi.ajp.161.12.2201
van Nimwegen, L., de Haan, L.,
van, B. N., Laan, W., van den,
B. W., and Linszen, D. (2008).
Obsessive-compulsive symptoms in
a randomized, double-blind study
with olanzapine or risperidone
in young patients with early psy-
chosis. J. Clin. Psychopharmacol. 28,
214–218. doi: 10.1097/JCP.0b01
3e318166f520
van Os, J., and Kapur, S. (2009).
Schizophrenia. Lancet 374,
635–645. doi: 10.1016/S0140-
6736(09)60995-8
van Os, J., Kenis, G., and Rutten, B.
P. (2010). The environment and
schizophrenia.Nature 468, 203–212.
doi: 10.1038/nature09563
van Os, J., Rutten, B. P., and Poulton,
R. (2008). Gene-environment
interactions in schizophre-
nia: review of epidemiological
findings and future directions.
Schizophr. Bull. 34, 1066–1082. doi:
10.1093/schbul/sbn117
Veenstra-VanderWeele, J., Kim, S.
J., Gonen, D., Hanna, G. L.,
Leventhal, B. L., and Cook, E. H.
Jr. (2001). Genomic organization
of the SLC1A1/EAAC1 gene and
mutation screening in early-onset
obsessive-compulsive disorder.
Mol. Psychiatry 6, 160–167. doi:
10.1038/sj.mp.4000806
Wendland, J. R., Moya, P. R., Timpano,
K. R., Anavitarte, A. P., Kruse,
M. R., Wheaton, M. G., et al.
(2009). A haplotype containing
quantitative trait loci for, SLC1A1
gene expression and its association
with obsessive-compulsive disorder.
Arch. Gen. Psychiatry 66, 408–416.
doi: 10.1001/archgenpsychiatry.
2009.6
Whiteside, S. P., Port, J. D., and
Abramowitz, J. S. (2004). A meta-
analysis of functional neuroimag-
ing in obsessive-compulsive disor-
der. Psychiatry Res. 132, 69–79. doi:
10.1016/j.pscychresns.2004.07.001
Whiteside, S. P., Port, J. D., Deacon,
B. J., and Abramowitz, J. S.
(2006). A magnetic resonance
spectroscopy investigation of
obsessive-compulsive disorder
and anxiety. Psychiatry Res.
146, 137–147. doi: 10.1016/j.
pscychresns.2005.12.006
Whitney, K. A., Fastenau, P. S., Evans,
J. D., and Lysaker, P. H. (2004).
Comparative neuropsychological
function in obsessive-compulsive
disorder and schizophrenia with
and without obsessive-compulsive
symptoms. Schizophr. Res. 69,
75–83. doi: 10.1016/j.schres.2003.
08.013
Woody, S. R., Steketee, G., and
Chambless, D. L. (1995). Reliability
and validity of the Yale-Brown
Obsessive-Compulsive Scale. Behav.
Res. Ther. 33, 597–605. doi: 10.1016/
0005-7967(94)00076-V
Yang, K. C., Su, T. P., and Chou,
Y. H. (2008). Effectiveness of
aripiprazole in treating obses-
sive compulsive symptoms. Prog.
Neuropsychopharmacol. Biol.
Psychiatry 32, 585–586. doi:
10.1016/j.pnpbp.2007.10.009
Yang, X. W., and Lu, X. H. (2011).
Molecular and cellular basis of
obsessive-compulsive disorder-
like behaviors: emerging view
from mouse models. Curr.
Opin. Neurol. 24, 114–118. doi:
10.1097/WCO.0b013e32834451fb
Zink, M., Englisch, S., Knopf, U.,
Kuwilsky, A., and Dressing, H.
(2007). Augmentation of clozapine
with valproic acid for clozapine-
induced obsessive compulsive
symptoms. Pharmacopsychiatry
40, 202–203. doi: 10.1055/s-2007-
985885
Zink, M., Knopf, U., and Kuwilsky,
A. (2006). Management of
clozapine-induced obsessive
compulsive symptoms in a man
with schizophrenia. Aust. N.Z.
J. Psychiatry 41, 293–294. doi:
10.1080/00048670601172806
Conflict of Interest Statement:
Frederike Schirmbeck was supported
by an unrestricted scientific grant of
Evangelisches Studienwerk. Mathias
Zink received unrestricted scientific
grants of the European Research
Advisory Board (ERAB), German
Research Foundation (DFG), Pfizer
Pharma GmbH, Servier and Bristol
Myers Squibb Pharmaceuticals; further
speaker and travel grants were pro-
vided from Astra Zeneca, Lilly, Pfizer
Pharma GmbH, Bristol Myers Squibb
Pharmaceuticals, Servier, Otsuka,
Roche and Janssen Cilag.
Received: 28 February 2013; accepted: 22
July 2013; published online: 09 August
2013.
Citation: Schirmbeck F and Zink M
(2013) Comorbid obsessive-compulsive
symptoms in schizophrenia: contribu-
tions of pharmacological and genetic
factors. Front. Pharmacol. 4:99. doi:
10.3389/fphar.2013.00099
This article was submitted to Frontiers
in Neuropharmacology, a specialty of
Frontiers in Pharmacology.
Copyright © 2013 Schirmbeck and
Zink. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License (CC BY).
The use, distribution or reproduction in
other forums is permitted, provided the
original author(s) or licensor are cred-
ited and that the original publication
in this journal is cited, in accordance
with accepted academic practice. No use,
distribution or reproduction is permit-
ted which does not comply with these
terms.
Frontiers in Pharmacology | Neuropharmacology August 2013 | Volume 4 | Article 99 | 14
